Characteristic | EGFR positive (%) | EGFR negative (%) | Pvalue | KRASWTa(%) | KRASMutb(%) | Pvalue |
---|---|---|---|---|---|---|
N = 73 (88.0%) | N = 17 (12.0%) | N = 63 (58.9%) | N = 44 (4119%) | |||
Age (years, mean ± SD) | 61.14 ± 11.81 | 65.80 ± 8.05 | 0.231 | 61.83 ± 10.49 | 61.86 ± 13.93 | 0.987 |
Gender | Â | Â | 0.787 | Â | Â | 0.119 |
Male | 47 (64.4) | 6 (60.0) | Â | 35 (55.6) | 31 (70.5) | Â |
Female | 26 (35.6) | 4 (40.0) | Â | 28 (44.4) | 13 (29.5) | Â |
Tumor size | Â | Â | 0.047 | Â | Â | 0.134 |
≥5 cm | 39 (53.4) | 2 (20.0) |  | 28 (44.4) | 26 (59.1) |  |
<5Â cm | 34 (46.6) | 8 (80.0) | Â | 35 (55.6) | 18 (40.9) | Â |
Tumor location | Â | Â | 0.055 | Â | Â | 0.098 |
Colon | 62 (84.9) | 6 (60.0) | Â | 46 (73.0) | 38 (86.4) | Â |
Rectum | 11 (15.1) | 4 (40.0) | Â | 17 (27.0) | 6 (13.6) | Â |
Histology | Â | Â | 0.862 | Â | Â | 0.873 |
Well | 2 (2.7) | 0 (00.0) | Â | 2 (3.2) | 1 (2.3) | 0.873 |
Moderately | 58 (79.5) | 8 (80.0) | Â | 49 (77.8) | 36 (81.8) | Â |
Poorly | 13 (17.8) | 2 (20.0) | Â | 12 (19.0) | 7 (15.9) | Â |
Histology | Â | Â | 0.866 | Â | Â | 0.676 |
Well + Moderately | 60 (82.2) | 8 (80.0) |  | 51 (81.0) | 37 (84.1) |  |
Poorly | 13 (17.8) | 2 (20.0) | Â | 12 (19.0) | 7 (15.9) | Â |
Tumor depth | Â | Â | 0.792 | Â | Â | 0.734 |
T1 | 1 (1.4) | 0 (0.0) | Â | 1 (1.6) | 0 (0.0) | Â |
T2 | 3 (4.1) | 1 (10.0) | Â | 3 (4.8) | 3 (6.8) | Â |
T3 | 48 (65.7) | 7 (70.0) | Â | 45 (71.4) | 29 (65.9) | Â |
T4 | 21 (28.8) | 2 (20.0) | Â | 14 (22.2) | 12 (27.3) | Â |
Lymph nodes metastases | Â | Â | 0.407 | Â | Â | 0.824 |
N0 | 17 (23.2) | 4 (40.0) | Â | 14 (22.2) | 10 (22.7) | Â |
N1 | 28 (38.4) | 2 (20.0) | Â | 25 (39.7) | 15 (34.1) | Â |
N2 | 28 (38.4) | 4 (40.0) | Â | 24 (38.1) | 19 (43.2) | Â |
Retrived LN c | 17.09 ± 8.04 | 14.40 ± 5.85 | 0.313 | 16.31 ± 8.36 | 16.25 ± 8.17 | 0.971 |
Vascular invasion | Â | Â | 0.756 | Â | Â | 0.863 |
Yes | 33 (45.2) | 4 (40.0) | Â | 29 (46.0) | 21 (47.7) | Â |
No | 40 (54.8) | 6 (60.0) | Â | 34 (54.0) | 23 (52.3) | Â |
Perineurial invasion | Â | Â | 0.968 | Â | Â | 0.539 |
Yes | 36 (49.3) | 5 (50.0) | Â | 32 (50.8) | 25 (56.8) | 0.539 |
No | 37 (50.7) | 5 (50.0) | Â | 31 (49.2) | 19 (43.2) | Â |
Pre-op serum CEA b level | Â | Â | 0.496 | Â | Â | 0.827 |
≥5 ng/ml | 58 (79.5) | 7 (70.0) |  | 49 (77.8) | 35 (79.5) |  |
<5Â ng/ml | 15 (20.5) | 3 (30.0) | Â | 14 (22.2) | 9 (20.5) | Â |
Post-op serum CEA b level | Â | Â | 0.568 | Â | Â | 0.799 |
≥5 ng/ml | 21 (28.8) | 4 (40.0) |  | 43 (68.3) | 29 (65.9) |  |
<5Â ng/ml | 46 (71.2) | 6 (60.0) | Â | 20 (31.7) | 15 (34.1) | Â |
Overall survival (months) | 22.08 ± 12.38 | 24.70 ± 9.91 | 0.523 | 23.04 ± 12.62 | 18.74 ± 11.39 | 0.074 |
Progression-free survival (months) | 9.65 ± 7.44 | 11.66 ± 6.16 | 0.417 | 10.22 ± 7.14 | 7.95 ± 6.75 | 0.101 |